Musi wa19 Chikumi, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakazivisa kuti IBI343 yeInnovent Biologics yakakurudzirwa kuti ibatanidzwe muchirongwa chekurapa kenza yepancreatic yakakwira kana kuti yakapararira, iyo ine CLDN18.2-positive, uye yakamborapwa kaviri kare.
IBI343 imushonga wekudzivirira mabhakitiriya unonzi recombinant anti-CLDN18.2 antibody-drug conjugate (ADC) (recombinant humanized anti-CLDN18.2 antibody-drug conjugate). Kana yabatana nemasero egomarara ane CLDN18.2, inopinda muCLDN18.2-dependent ADC internalization uye inoburitsa cytotoxic payload, zvichikonzera kukuvara kweDNA uye pakupedzisira zvichikonzera apoptosis yemasero egomarara.
Musi wa9 Zvita, 2024, data razvino kubva mukuyedzwa kwekiriniki kwePhase I (NCT05458219) reIBI343 mu advanced pancreatic ductal adenocarcinoma (PDAC) rakaunzwa paMusangano weGore weEuropean Society for Medical Oncology Asia (ESMO Asia).
Varwere vese makumi mana nevatatu vane CLDN18.2-positive advanced PDAC vakarapwa neIBI343. Zvakabuda zvakaratidza kuti huwandu hwemhinduro dzinoshanda (ORR) hwakasvika 32.6%, huwandu hwemhinduro dzinoshanda (cORR) hwakasvika 23.3%, uye huwandu hwekutonga chirwere hwakasvika 81.4%. Nguva yepakati yemhinduro (mDoR) yaive mwedzi 7.0, uye huwandu hweDoR hwemwedzi mitanhatu hwaive 63%, uye huwandu hwekugara kwenguva refu husina kusimba (PFS) hwaive mwedzi 5.3.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Nguva yekutumira: Chikumi-19-2025